This study is in progress, not accepting new patients

Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer

a study on Prostate Cancer Radiation Toxicity

Summary

Eligibility
for males ages 18-120 (full criteria)
Location
at San Francisco, California
Dates
study started
completion around
Principal Investigator
by Mack Roach, MD
Headshot of Mack Roach
Mack Roach

Description

Summary

RATIONALE: Gathering information about the Gleason score, prostate-specific antigen (PSA) level, and cancer stage from patients who have undergone radiation therapy for prostate cancer may help doctors predict how patients respond to treatment and help plan the best treatment.

PURPOSE: This clinical trial is studying the Gleason score, PSA level, and cancer stage in predicting outcome in patients who have undergone radiation therapy for localized prostate cancer.

Official Title

Pre-Operative Gleason Score and PSA and Clinical Stage in Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer

Details

OBJECTIVES:

  • Evaluate the value of the pre-operative Gleason score, prostate-specific antigen level, and clinical stage in predicting the risk of failure and death in patients who have undergone radiotherapy for localized prostate cancer.

OUTLINE: This is a multicenter study.

Patient medical records are reviewed to collect data about pre-treatment prostate biopsy, assigned Gleason score, prostate-specific antigen level, and radionucleotide bone scan.

Patients complete a Bowel Toxicity questionnaire to assess quality of life related to acute and long-term bowel toxicity after radiotherapy.

Keywords

Prostate Cancer, Radiation Toxicity, recurrent prostate cancer, stage IIB prostate cancer, stage IIA prostate cancer, stage III prostate cancer, stage I prostate cancer, stage IV prostate cancer, adenocarcinoma of the prostate, Prostatic Neoplasms, medical chart review, quality-of-life assessment, brachytherapy, radiation therapy

Eligibility

For males ages 18-120

DISEASE CHARACTERISTICS:

  • Diagnosis of localized adenocarcinoma of the prostate
  • Has undergone radiotherapy (external beam radiotherapy and/or brachytherapy) with or without hormonal therapy for adenocarcinoma of the prostate in the University of California, San Francisco (UCSF) Radiation Oncology Department at San Francisco General Hospital or Veterans Administration Medical Center of San Francisco between 1987 and 2006

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics

Location

  • UCSF
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Mack Roach, MD
    Professor, Radiation Oncology, School of Medicine. Authored (or co-authored) 305 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT00769223
Study Type
Observational
Participants
About 3561 people participating
Last Updated